Abbott Laboratories, ABT is in the exchange NYSE and its industry is Medical Appliances & Equipment in the sector of Healthcare. Based in USA, Abbott Laboratories, ABT has a market cap of 62076.62. Since its IPO date on the 4/6/1983, Abbott Laboratories, ABT performance year to date is -4.50%. Today Abbott Laboratories, ABT has gained -1.06%, with a current price of 42.1.
Ownership of the company is 0.30% for insider ownership while institutional ownership is 73.90%. The management of the company have seen the company have a payout ratio of 66.50%. Return of assets are at 5.60%, with return on investment at 7.70%.
In terms of debt levels and profit levels, Abbott Laboratories, ABT is seeing a long-term debt/equity of 0.29. While Total debt/equity is 0.41. With a profit margin of 11.10%, this is combined with a gross margin of 56.90%, and operating margin of 14.00%. Abbott Laboratories ability to meet debt levels, with a current ratio of 1.5, while the quick ratio is 1.2.
For the last year Abbott Laboratories, ABT has seen a EPS growth of 53.50%. A performance for the year of 4.22%. The 52-week high is -8.06%, and the 52-week low is 18.38%. The average volume for Abbott Laboratories, ABT is 5863900.
With a target price of 7.43, can Abbott Laboratories, ABT reach this target? Looking at the value indicators of Abbott Laboratories, ABT. Abbott Laboratories has a P/E of 32.31 and a forward P/E of 17.15. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.36. Abbott Laboratories also has a P/S and a P/B of 3.02 and 3 respectively. For P/cash, Abbott Laboratories has a value of 13.99, while it is 307.31 for P/free cash flow.
At the current price of 42.1, Abbott Laboratories has a dividend yield of 2.47%. We see a return on equity of 10.90%.
Looking more long-term Abbott Laboratories, is projected to get an EPS growth for the next five years of 9.61%. In the short-term an EPS growth of 11.69% in the next year is forecasted. This is after a EPS growth of 53.50% for this year and for the last five years a -10.30% growth has been seen.